EDAP TMS (EDAP) has released an update.
EDAP TMS reported a strong third quarter in 2024, with a notable 48.2% increase in HIFU revenue and continued growth in Focal One procedures. The company is enhancing its Focal One platform by integrating AI technology from Avenda Health and is seeing favorable reimbursement adjustments for 2025. Additionally, EDAP is advancing clinical trials for benign prostatic hyperplasia and endometriosis, positioning itself for a robust year-end performance.
For further insights into EDAP stock, check out TipRanks’ Stock Analysis page.
